Alerts will be sent to your verified email
Verify EmailVIVIMEDLAB
|
Vivimed Labs
|
Biofil Chem & Pharma
|
Bharat Immunological
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
US DMF Filings
|
150.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
0.14 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
184.61 % | 4.39 % | 0.0 |
|
5yr average Equity Multiplier
|
-33.72 | 2.06 | 3.08 |
|
5yr Average Asset Turnover Ratio
|
0.27 | 0.95 | 0.61 |
|
5yr Avg Net Profit Margin
|
-54.08 % | 2.38 % | -18.38 % |
|
Price to Book
|
0.0 | 2.53 | 0.95 |
|
P/E
|
0.0 | 19.39 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
184.52 Days | 75.63 Days | 206.63 Days |
|
Inventory Days
|
244.76 Days | 28.27 Days | 125.06 Days |
|
Days Receivable
|
246.32 Days | 389.8 Days | 61.4 Days |
|
Days Payable
|
159.64 Days | 203.89 Days | 117.81 Days |
|
5yr Average Interest Coverage Ratio
|
-6.61 | 23.53 | -2.32 |
|
5yr Avg ROCE
|
-13.87 % | 6.37 % | -44.64 % |
|
5yr Avg Operating Profit Margin
|
-26.56 % | 3.78 % | -18.7 % |
|
5 yr average Debt to Equity
|
-13.68 | 0.03 | 0.71 |
|
5yr CAGR Net Profit
|
-14.97 % | -14.7 % | 23.51 % |
|
5yr Average Return on Assets
|
-10.44 % | 2.37 % | -10.1 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
7.57 % | 46.79 % | 59.25 % |
|
Share Pledged by Promoters
|
15.18 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-13.37 % | -0.03 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Vivimed Labs
|
Biofil Chem & Pharma
|
Bharat Immunological
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
-
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|